tiprankstipranks
Advertisement
Advertisement

DYN Stock Latest News

Trump plans to fire FDA commissioner Marty Makary, WSJ reports
The FlyTrump plans to fire FDA commissioner Marty Makary, WSJ reports
24h ago
DYN
RNA
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
PremiumRatings
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
18d ago
DYN
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
PremiumCompany Announcements
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
23d ago
DYN
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
26d ago
DYN
RNA
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
PremiumRatings
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
2M ago
DYN
Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen
PremiumThe FlyDyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen
2M ago
DYN
Dyne Therapeutics initiates Phase 3 Harmonia trial of Z-Basivarsen in DM1
Premium
The Fly
Dyne Therapeutics initiates Phase 3 Harmonia trial of Z-Basivarsen in DM1
2M ago
DYN
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
2M ago
AZN
BMY
Dyne Therapeutics price target lowered to $47 from $50 at Morgan Stanley
PremiumThe Fly
Dyne Therapeutics price target lowered to $47 from $50 at Morgan Stanley
2M ago
DYN
Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
PremiumThe Fly
Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
2M ago
DYN
Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
PremiumThe Fly
Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
2M ago
DYN
Dyne Therapeutics announces upcoming presentations at MDA Conference
PremiumThe Fly
Dyne Therapeutics announces upcoming presentations at MDA Conference
3M ago
DYN
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
PremiumThe FlyDyne announces MHLW in Japan granted ODD for zeleciment basivarsen
4M ago
DYN
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
Premium
Company Announcements
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
4M ago
8K
DYN
Dyne Therapeutics Appoints Vikram Karnani to Board
Premium
Company Announcements
Dyne Therapeutics Appoints Vikram Karnani to Board
5M ago
8K
DYN
Dyne Therapeutics appoints Vikram Karnani to board of directors
PremiumThe Fly
Dyne Therapeutics appoints Vikram Karnani to board of directors
5M ago
DYN
COLL
Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
PremiumThe Fly
Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
5M ago
DYN
Dyne Therapeutics price target raised to $39 from $36 at Stifel
PremiumThe Fly
Dyne Therapeutics price target raised to $39 from $36 at Stifel
5M ago
DYN
Dyne Therapeutics Announces Upsized Public Offering
PremiumCompany Announcements
Dyne Therapeutics Announces Upsized Public Offering
5M ago
8K
DYN
Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
PremiumThe FlyAmazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
5M ago
M
NE
Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
Premium
The Fly
Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
5M ago
DYN
Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
Premium
The Fly
Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
5M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >